$359.00
Manufacturer: Ukraine
Immunostimulants. ATX code L03A X.
The drug is administered subcutaneously. To prepare a solution for injection, use a 0.9% sodium chloride solution as a solvent. For subcutaneous administration of the drug, use 1 ml of the solvent.
herpetic infection.
The standard course of treatment for recurrent herpes infection includes injections of the drug at a dose of 1 mg subcutaneously every other day, a total of 3 injections per course. In case of insufficient effectiveness and in the absence of pronounced side effects during the next relapse, it is recommended to prescribe injections at a dose of 1 mg every other day, a total of 6-9 injections per course.
Hepatitis.
In the treatment of acute hepatitis B of mild to moderate severity, the drug should be administered after confirming the diagnosis at a dose of 1 mg 3 times a week for 3 weeks (9 injections in total).
Chronic papillomavirus infection caused by oncogenic human papillomaviruses.
The standard course of treatment for infections caused by oncogenic types of human papillomavirus, including injections of the drug at a dose of 1 mg every other day, for a total of 6 injections.
Description
Ingredients
active ingredient: alloferon;
1 ampoule or bottle of alloferon 1 mg.
Pharmacotherapeutic group
Immunostimulants. ATX code L03A X.
Pharmacodynamics
Alloferon is an oligopeptide. Alloferon is an effective inducer of the synthesis of endogenous alpha and gamma interferons and an activator of the natural killer system. The agent stimulates the recognition and lysis of defective cells by cytotoxic lymphocytes. During the experiments, the drug was found to be highly effective against infections caused by influenza A and B viruses, hepatitis B, herpes and human papillomavirus. Alloferon does not cause general toxicity, allergic reactions, does not have mutagenic, carcinogenic and embryotoxic effects, does not affect reproductive function.
Indications
As part of complex therapy, chronic recurrent herpes type I-II, acute viral hepatitis B (mild and moderate severity). Chronic papillomavirus infection caused by oncogenic human papillomaviruses.
Contraindications
Hypersensitivity to the drug. Autoimmune diseases.
Use during pregnancy or lactation
During pregnancy and lactation, the drug is contraindicated.
Dosage and administration
The drug is administered subcutaneously. To prepare a solution for injection, use a 0.9% sodium chloride solution as a solvent. For subcutaneous administration of the drug, use 1 ml of the solvent.
herpetic infection.
The standard course of treatment for recurrent herpes infection includes injections of the drug at a dose of 1 mg subcutaneously every other day, a total of 3 injections per course. In case of insufficient effectiveness and in the absence of pronounced side effects during the next relapse, it is recommended to prescribe injections at a dose of 1 mg every other day, a total of 6-9 injections per course.
Hepatitis.
In the treatment of acute hepatitis B of mild to moderate severity, the drug should be administered after confirming the diagnosis at a dose of 1 mg 3 times a week for 3 weeks (9 injections in total).
Chronic papillomavirus infection caused by oncogenic human papillomaviruses.
The standard course of treatment for infections caused by oncogenic types of human papillomavirus, including injections of the drug at a dose of 1 mg every other day, for a total of 6 injections.
Recent Reviews